Transcranial Doppler blood velocity measurement-the effect of changes in velocity profile

Authors: Lunt, M.J., Jenkinson, D.F. and Kerr, D.

Journal: Ultrasound in Medicine and Biology

Volume: 26

Issue: 7

Pages: 1145-1151

ISSN: 0301-5629

DOI: 10.1016/S0301-5629(00)00263-5

Abstract:

Transcranial Doppler (TCD) units measure blood velocity in the middle cerebral artery (MCA) and are used to examine the effects of pharmacological agents. The units actually measure the average of the maximum blood velocity envelope (aveV(max)) and it is assumed that changes in aveV(max) follow changes in the true mean velocity (aveV(mean)). This may not be true if there are changes in velocity profile. Results from previous TCD studies using acetazolamide (ACZ) and caffeine were examined for evidence for changes in velocity profile. ACZ increased aveV(max) by 21% (95% CI 13 to 29%) and aveV(mean) by 14% (95% CI 9 to 19%). Caffeine decreased aveV(max) by 8% (95% CI 4 to 12%) and aveV(mean) by 5% (95% CI 4% increase to 13% decrease). In both cases, the true change, measured using aveV(mean) was lower, indicating possible changes in velocity profile. We conclude that the possibility of changes in velocity profile must be considered when using TCD to quantify changes in blood velocity. Copyright (C) 2000 World Federation for Ultrasound in Medicine and Biology.

Source: Scopus

Transcranial Doppler blood velocity measurement--the effect of changes in velocity profile.

Authors: Lunt, M.J., Jenkinson, D.F. and Kerr, D.

Journal: Ultrasound Med Biol

Volume: 26

Issue: 7

Pages: 1145-1151

ISSN: 0301-5629

DOI: 10.1016/s0301-5629(00)00263-5

Abstract:

Transcranial Doppler (TCD) units measure blood velocity in the middle cerebral artery (MCA) and are used to examine the effects of pharmacological agents. The units actually measure the average of the maximum blood velocity envelope (aveV(max)) and it is assumed that changes in aveV(max) follow changes in the true mean velocity (aveV(mean)). This may not be true if there are changes in velocity profile. Results from previous TCD studies using acetazolamide (ACZ) and caffeine were examined for evidence for changes in velocity profile. ACZ increased aveV(max) by 21% (95% CI 13 to 29%) and aveV(mean) by 14% (95% CI 9 to 19%). Caffeine decreased aveV(max) by 8% (95% CI 4 to 12%) and aveV(mean) by 5% (95% CI 4% increase to 13% decrease). In both cases, the true change, measured using aveV(mean) was lower, indicating possible changes in velocity profile. We conclude that the possibility of changes in velocity profile must be considered when using TCD to quantify changes in blood velocity.

Source: PubMed

Transcranial Doppler blood velocity measurement - The effect of changes in velocity profile

Authors: Lunt, M.J., Jenkinson, D.F. and Kerr, D.

Journal: ULTRASOUND IN MEDICINE AND BIOLOGY

Volume: 26

Issue: 7

Pages: 1145-1151

ISSN: 0301-5629

DOI: 10.1016/S0301-5629(00)00263-5

Source: Web of Science (Lite)

Transcranial Doppler blood velocity measurement-the effect of changes in velocity profile

Authors: Lunt, M.J., Jenkinson, D.F. and Kerr, D.

Journal: Ultrasound in Medicine and Biology

Volume: 26

Pages: 1145-1151

ISSN: 0301-5629

DOI: 10.1016/S0301-5629(00)00263-5

Abstract:

Transcranial Doppler (TCD) units measure blood velocity in the middle cerebral artery (MCA) and are used to examine the effects of pharmacological agents. The units actually measure the average of the maximum blood velocity envelope (aveVmax) and it is assumed that changes in aveVmax follow changes in the true mean velocity (aveVmean). This may not be true if there are changes in velocity profile. Results from previous TCD studies using acetazolamide (ACZ) and caffeine were examined for evidence for changes in velocity profile. ACZ increased aveVmax by 21% (95% CI 13 to 29%) and aveVmean by 14% (95% CI 9 to 19%). Caffeine decreased aveVmax by 8% (95% CI 4 to 12%) and aveVmean by 5% (95% CI 4% increase to 13% decrease). In both cases, the true change, measured using aveVmean was lower, indicating possible changes in velocity profile. We conclude that the possibility of changes in velocity profile must be considered when using TCD to quantify changes in blood velocity.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TD2-41GNKW7-B&_user=1682380&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000011378&_version=1&_urlVersion=0&_userid=1682380&md5=33653f715b24cbcc1969a06aa2cd6ae2

Source: Manual

Preferred by: David Kerr

Transcranial Doppler blood velocity measurement--the effect of changes in velocity profile.

Authors: Lunt, M.J., Jenkinson, D.F. and Kerr, D.

Journal: Ultrasound in medicine & biology

Volume: 26

Issue: 7

Pages: 1145-1151

eISSN: 1879-291X

ISSN: 0301-5629

DOI: 10.1016/s0301-5629(00)00263-5

Abstract:

Transcranial Doppler (TCD) units measure blood velocity in the middle cerebral artery (MCA) and are used to examine the effects of pharmacological agents. The units actually measure the average of the maximum blood velocity envelope (aveV(max)) and it is assumed that changes in aveV(max) follow changes in the true mean velocity (aveV(mean)). This may not be true if there are changes in velocity profile. Results from previous TCD studies using acetazolamide (ACZ) and caffeine were examined for evidence for changes in velocity profile. ACZ increased aveV(max) by 21% (95% CI 13 to 29%) and aveV(mean) by 14% (95% CI 9 to 19%). Caffeine decreased aveV(max) by 8% (95% CI 4 to 12%) and aveV(mean) by 5% (95% CI 4% increase to 13% decrease). In both cases, the true change, measured using aveV(mean) was lower, indicating possible changes in velocity profile. We conclude that the possibility of changes in velocity profile must be considered when using TCD to quantify changes in blood velocity.

Source: Europe PubMed Central